ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?

[1]  A. Parikh,et al.  Investigating the Use of Circulating Tumor DNA in Early-Stage Colon Cancer. , 2022, Oncology.

[2]  B. Vogelstein,et al.  318MO Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC) , 2022, Annals of Oncology.

[3]  P. Kasi,et al.  Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Lindberg,et al.  ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  C. Montagut,et al.  Liquid Biopsy for Precision Adjuvant Chemotherapy in Colon Cancer. , 2022, The New England journal of medicine.

[6]  J. Ptak,et al.  Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. , 2022, The New England journal of medicine.

[7]  G. Chatellier,et al.  Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). , 2021, European journal of cancer.

[8]  C. Andersen,et al.  Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences , 2021, Clinical Cancer Research.

[9]  D. Aust,et al.  The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). , 2021, Clinical colorectal cancer.

[10]  A. Gangi,et al.  Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer , 2021, Cancers.

[11]  S. Shchegrova,et al.  Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases , 2021, JCO precision oncology.

[12]  P. Laurent-Puig,et al.  Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial , 2021, Clinical Cancer Research.

[13]  C. Montagut,et al.  ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC) , 2021, Cancers.

[14]  P. Ding,et al.  Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer , 2021, Journal of Hematology & Oncology.

[15]  J. Ptak,et al.  Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study , 2021, PLoS medicine.

[16]  E. Oki,et al.  CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer , 2021, Cancer science.

[17]  Jeffrey W. Clark,et al.  Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer , 2021, Clinical Cancer Research.

[18]  C. Ding,et al.  Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy , 2021, Proceedings of the National Academy of Sciences.

[19]  S. Jeffrey,et al.  Liquid biopsy enters the clinic — implementation issues and future challenges , 2021, Nature Reviews Clinical Oncology.

[20]  R. Labianca,et al.  Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Gibbs,et al.  ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm , 2021, Cancers.

[22]  J. Ptak,et al.  Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies , 2020, International journal of cancer.

[23]  V. Ferrer,et al.  ctDNA as a cancer biomarker: A broad overview. , 2020, Critical reviews in oncology/hematology.

[24]  R. Labianca,et al.  Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  O. W. Lindwasser,et al.  ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper , 2020, Nature Reviews Clinical Oncology.

[26]  Yusuke Nakamura,et al.  P-120 Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (trial in progress) , 2020 .

[27]  C. Lepage,et al.  "Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial". , 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[28]  R. Labianca,et al.  The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. , 2020 .

[29]  C. Andersen,et al.  IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer – intervention trial 2. Study protocol , 2020, Acta oncologica.

[30]  D. Moro,et al.  Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Ptak,et al.  Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. , 2019, JAMA oncology.

[32]  P. Laurent-Puig,et al.  Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration , 2019, Annals of Oncology.

[33]  J. Ptak,et al.  Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. , 2019, JAMA oncology.

[34]  S. Shchegrova,et al.  Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer , 2019, JAMA oncology.

[35]  Mingwei Li,et al.  Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data. , 2019, Cancer biomarkers : section A of Disease markers.

[36]  T. Yoshino,et al.  Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. , 2018, The oncologist.

[37]  P. Bruzzi,et al.  The urgent need to improve the tools to assess clinical benefit and value of cancer treatment. , 2017, European journal of cancer.

[38]  H. Nielsen,et al.  Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer , 2017, Clinical Cancer Research.

[39]  S. Mortimer,et al.  Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence. , 2017 .

[40]  E. Van Cutsem,et al.  Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians , 2016, Cancers.

[41]  R. Strausberg,et al.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.

[42]  C. Tournigand,et al.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[44]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[45]  D. Sargent,et al.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Labianca,et al.  Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[48]  Daniel J Sargent,et al.  End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Yuman Fong,et al.  Actual 10-year survival after resection of colorectal liver metastases defines cure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..